Consolidation is not just likely, it is already underway

India’s IVF sector has historically been dominated by standalone clinics and clinician-led practices. With Gaudium becoming India’s first listed fertility services company, what does this milestone indicate about the sector’s transition towards a more structured and investable healthcare market?

This marks a structural shift in India’s fertility landscape. Historically, IVF services have been fragmented and largely clinician-led. Our listing signals the emergence of an organised, scalable, and governance-driven fertility care ecosystem.

Gaudium has evolved from a single centre into a pan-India network of over 30 locations, built on a hub-and-spoke model that ensures both accessibility and consistency in outcomes.

This milestone reinforces that fertility care is now being recognised as a credible and investable healthcare segment, supported by strong demand fundamentals and scalable operating models.

As fertility care platforms begin engaging with capital markets, how does access to public funding change the way organisations plan expansion, invest in specialised infrastructure, and scale operations compared to the traditional organic growth model?

Access to public funding transforms expansion from a gradual process into a strategic and accelerated journey. Traditionally, growth was largely dependent on internal accruals, limiting scale to one centre at a time. With capital market access, we can invest more proactively in new IVF centres, advanced embryology laboratories, and adjacent healthcare capabilities through our subsidiary ecosystem.

This allows us to deploy the hub-and-spoke model more systematically, standardise access to advanced technologies, and attract high-quality medical talent, while continuing to maintain strong clinical outcomes and patient-centric care.

Gaudium has grown from a single clinic in 2015 to a network of more than 30 centres across North and Central India. From a market development perspective, what factors are enabling organised fertility platforms to scale rapidly across Tier 1 and Tier 2 cities?

Several converging factors are enabling this scale. Rising infertility rates, delayed parenthood, and lifestyle changes have significantly expanded the patient base. At the same time, increasing awareness and reduced social stigma have encouraged more couples to actively seek fertility treatment. Operationally, the hub-and-spoke model enables full-service hubs in metro cities while extending consultations and basic care through spokes in Tier 2 and Tier 3 markets, improving both access and efficiency.

Additionally, a trusted brand built over years of clinical expertise and consistent outcomes enables faster patient acquisition and credibility in new geographies.

With the IVF market projected to grow significantly in the coming years, how are fertility service providers rethinking their business models to capture this opportunity while maintaining clinical outcomes and operational efficiency?

The focus is shifting towards building standardised, technology-enabled, and scalable healthcare platforms. At Gaudium, we have implemented SOP-driven processes that reduce dependence on individual practitioners and ensure consistency in clinical outcomes across centres.

We are also strengthening our capabilities through advanced lab infrastructure, cryopreservation technologies, and next-generation embryology practices, which improve both success rates and operational efficiency.

As investor interest in fertility care increases, do you foresee consolidation becoming a defining feature of the sector, with larger networks acquiring smaller clinics to build scale and brand trust?

Consolidation is not just likely, it is already underway.

Well-capitalised platforms are increasingly positioned to integrate standalone clinics into structured networks with standardised protocols, advanced technology, and stronger brand equity. For smaller clinics, this provides access to resources such as centralised systems, professional management, and broader reach. For patients, it translates into more consistent quality of care. At an industry level, this will reduce fragmentation and accelerate the shift towards organised fertility platforms.

Looking ahead, what key market shifts do you anticipate in India’s fertility services landscape over the next five years, particularly in terms of organised players, capital inflow and the emergence of fertility care as a distinct healthcare investment category?

We expect three major shifts. First, organised players will gain a larger share of the market as patients increasingly prioritise reliability, transparency, and outcomes.

Second, fertility care will firmly establish itself as a high-growth healthcare investment category, supported by strong market fundamentals and increasing capital inflow.

Third, technology will play a transformative role. Advancements in embryology, fertility preservation, and lab automation will significantly improve success rates and expand access across geographies.

India is poised to become one of the fastest-growing IVF markets globally, with its share expected to nearly double over the next decade